Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer

PURPOSE: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy are recommended for first-line treatment of hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) advanced breast cancer (ABC). However, not all CDK4/6i trials have reported significant...

Descripción completa

Detalles Bibliográficos
Autores principales: Fasching, Peter A, Delea, Thomas E, Lu, Yen-Shen, De Boer, Richard, Hurvitz, Sara A, Moynahan, Aaron, Chandiwana, David, Lanoue, Brad, Hu, Huilin, Thuerigen, Astrid, O’Shaughnessy, Joyce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570288/
https://www.ncbi.nlm.nih.gov/pubmed/34754238
http://dx.doi.org/10.2147/CMAR.S325043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570288/
https://www.ncbi.nlm.nih.gov/pubmed/34754238
http://dx.doi.org/10.2147/CMAR.S325043

Ejemplares similares